Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: An exploratory economic evaluation of personalized medicine

Molecular Diagnosis and Therapy

Volumn 16, Issue 6, 2012, Pages 389-399

  Djalalov, Sandjar ^a,b   Yong, Jean ^a,b   Beca, Jaclyn ^a,b   Black, Sandra ^c,d   Saposnik, Gustavo ^a,c   Musa, Zahra ^b   Siminovitch, Katherine ^c,e   Moretti, Myla ^f   Hoch, Jeffrey S ^a,b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Pharmacoeconomics Research Unit   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; DONEPEZIL;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; GENETIC SCREENING; HEALTH CARE COST; HIDDEN MARKOV MODEL; HUMAN; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS;

AGED; AGED, 80 AND OVER; AMNESIA; CANADA; CASE-CONTROL STUDIES; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; GENETIC TESTING; HUMANS; INDANS; INDIVIDUALIZED MEDICINE; MARKOV CHAINS; MILD COGNITIVE IMPAIRMENT; MOLECULAR TARGETED THERAPY; NOOTROPIC AGENTS; PIPERIDINES; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; STANDARD OF CARE;

EID: 84873452414     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-012-0010-7     Document Type: Article

References (53)

1. Alzheimer's Disease Education and Referral Centre, National Institute on Aging About Alzheimer's disease: Alzheimer's basics. http://www.nia.nih.gov/ alzheimers/topics/alzheimers-basics. Accessed 25 Oct 2012.
2. Alzheimer Society Canada. Rising tide: the impact of dementia on Canadian society. http://www.alzheimer.ca/en/Get-involved/Raise-your-voice/Rising-Tide/ Rising-tide-summary. Accessed 25 Oct 2012.
3. Petersen RC. Mild cognitive impairment: aging to Alzheimer's disease. New York: Oxford University Press; 2003.
4. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-88.
5. Korovaitseva GI, Shcherbatykh TV, Selezneva NV, et al. Genetic association between the apolipoprotein E (ApoE) gene alleles and various forms of Alzheimer's disease [in Russian]. Genetika. 2001;37(4):529-35.
6. Goldman JS, Hou CE. Early-onset Alzheimer disease: when is genetic testing appropriate? Alzheimer Dis Assoc Disord. 2004;18(2):65-7.
7. Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology. 1996;46(1):149-54.
8. Hsiung GY, Sadovnick AD, Feldman H. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. CMAJ. 2004;171(8):863-7.
9. Fleck LM. Just caring: the moral and economic costs of APOE genotyping for Alzheimer's disease. Ann NY Acad Sci. 1996;802:128-38.
10. Chertkow H, Massoud F, Nasreddine Z, et al. Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia. CMAJ. 2008;178(10):1273-85.
11. Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004;63(4):651-7.
12. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology. 1999;52(6):1138-45.
13. O'Brien BJ, Goeree R, Hux M, et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc. 1999;47(5):570-8.
14. Feldman N, Gauthier S, Hecker J, et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology. 2004;63:644-50.
15. Kasuya M, Meguro K. Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model. Arch Gerontol Geriatr. 2010;50(3):295-9.
16. Khan KS, Kunz R, Kleijnen J, et al. Systematic reviews to support evidence-based medicine: how to review and apply findings of healthcare research. London: Royal Society of Medicine Press; 2003.
17. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
18. Davis HS, Rockwood K. Conceptualization of mild cognitive impairment: a review. Int J Geriatr Psychiatry. 2004;19(4):313-9.
19. van der Flier WM, Pijnenburg YA, Schoonenboom SN, et al. Distribution of APOE genotypes in a memory clinic cohort. Dement Geriatr Cogn Disord. 2008;25(5):433-8.
20. Norberg J, Graff C, Almkvist O, et al. Regional differences in effects of APOE epsilon4 on cognitive impairment in non-demented subjects. Dement Geriatr Cogn Disord. 2011;32(2):135-42.
21. Statistics Canada. Census: population and dwelling counts. http://www12.statcan.ca/census-recensement/2006/dp-pd/hlt/97-550/Index.cfm?TPL= P1C&Page=RETR&LANG=Eng&T=101. Accessed 29 Oct 2012.
22. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59(2):198-205.
23. Dodge HH, Shen C, Pandav R, et al. Functional transitions and active life expectancy associated with Alzheimer disease. Arch Neurol. 2003;60(2):253-9.
24. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia: meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119(4):252-65.
25. Neumann PJ, Sandberg EA, Araki SS, et al. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Med Decis Making. 2000;20(4):413-22.
26. Jonsson L, Andreasen N, Kilander L, et al. Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord. 2006;20(1):49-55.
27. Kerner DN, Patterson TL, Grant I, Kaplan RM. Validity of the quality of well-being scale for patients with Alzheimer's disease. J Aging Health. 1998;10(1):44-61.
28. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-4.
29. Ministry of Health and Long-Term Care. Ontario drug benefit formulary/comparative drug index no. 41. http://www.health.gov.on.ca/english/ providers/program/drugs/formulary/edition-41.pdf. Accessed 25 Oct 2012.
30. Ministry of Health and Long-Term Care. Schedule of benefits for physician services under the Health Insurance Act. http://www.health.gov.on.ca/english/ providers/program/ohip/sob/physserv/physserv-mn.html. Accessed 25 Oct 2012.
31. Ministry of Health and Long-Term Care. Schedule of benefits for laboratory services: April 1, 1999. http://www.health.gov.on.ca/english/ providers/program/ohip/sob/lab/lab-services-sched-01-19990401.pdf. Accessed 29 Oct 2012.
32. SpectraCell Laboratories. SpectraCell Laboratories offers apolipoprotein E genetic testing [media release]. http://www.spectracell.com/media/press- release-apo-e.pdf. Accessed 25 Oct 2012.
33. Miller F, Hurley J, Morgan S, et al. Predictive genetic tests and health care cost: final report prepared for the Ontario Ministry of Health and Long Term Care. http://www.health.gov.on.ca/fr/common/ministry/publications/reports/ geneticsrep02/chepa-rep.pdf. Accessed 25 Oct 2012.
34. Wong CL, Bansback N, Lee PE, Anis AH. Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia. Can J Neurol Sci. 2009;36(6):735-9.
35. Hux MJ, O'Brien BJ, Iskedjian M, et al. Relation between severity of Alzheimer's disease and costs of caring. CMAJ. 1998;159(5):457-65.
36. Hogan DB, Thierer DE, Ebly EM, Parhad IM. Progression and outcome of patients in a Canadian dementia clinic. Can J Neurol Sci. 1994;21(4):331-8.
37. Statistics Canada. Consumer price index, health and personal care. http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/cpis01a-eng.htm. Accessed 25 Oct 2012.
38. Oostenbrink JB, Al MJ, Oppe M, Rutten-van Molken MP. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. Value Health. 2008;11(7):1070-80.
39. Perlis RH, Ganz DA, Avorn J, et al. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol. 2005;25(5):427-34.
40. Lonning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol. 2006;17(2):217-25.
41. Rice DP, Fox PJ, Max W, et al. The economic burden of Alzheimer's disease care. Health Aff (Millwood). 1993;12(2):164-76.
42. Fagnani F, Lafuma A, Pechevis M, et al. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications. Dement Geriatr Cogn Disord. 2004;17(1-2):5-13.
43. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med. 1998;338(8):506-11.
44. Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156(5):445-53.
45. Elias-Sonnenschein LS, Viechtbauer W, Ramakers IH, et al. Predictive value of APOE-epsilon4 allele for progression from MCI to AD-type dementia: a meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82(10):1149-56.
46. Novartis Clinical Trial Results Database. A prospective, randomized, multicenter, double blind, placebo-controlled, parallel-group study of the effect of rivastigmine on the time to clinical diagnosis of Alzheimer's disease in subjects with mild cognitive impairment (MCI). http://www.novctrd.com/ ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1886. Accessed 25 Oct 2012.
47. Farias ST, Mungas D, Reed BR, et al. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol. 2009;66(9):1151-7.
48. Luppa M, Heinrich S, Matschinger H, et al. Direct costs associated with mild cognitive impairment in primary care. Int J Geriatr Psychiatry. 2008;23:963-71.
49. Williams MM, Xiong C, Morris JC, Galvin JE. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology. 2006;67(11):1935-41.
50. Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomized trials. PLoS Med. 2007;4(11):e338.
51. Lopez OL, Jagust WJ, DeKosky ST, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study, part 1. Arch Neurol. 2003;60:1385-9.
52. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43(5):436-41.
53. Cacabelos R, Martinez-Bouza R. Genomics and pharmacogenomics of dementia. CNS Neurosci Ther. 2011;17(5):566-76.